Research into other inflammatory mediators, such as IL-6, TNF-α, and monocyte chemoattractant protein-1, with potential therapeutic options for preventing the rapid progression of atherosclerosis in NCVs is ongoing. This evidence concerns the gene TNF and atherosclerosis.